Synagis (Palivizumab)

Synagis is a medicine used to protect babies and young children who are at high risk from getting seriously sick with Respiratory Syncytial Virus (RSV). It's given as an injection, usually once a month during RSV season. It helps prevent severe RSV infections, which can sometimes lead to hospital stays.

Brand names:Synagis
Medication

What people taking Synagis (Palivizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Synagis (Palivizumab) for Respiratory Syncytial Virus (RSV) Infection?

NameHow it went

About Synagis (Palivizumab)

What It's For

Palivizumab, sold as Synagis, is a preventive antibody injection that helps protect certain high-risk babies and toddlers from serious lung infection caused by respiratory syncytial virus (RSV). RSV causes ordinary colds in most people, but in very young or medically fragile children it can spread into the small airways and lungs and lead to a hospital stay. In the US it was approved for three groups of children at the start of RSV season: babies born at 35 weeks of pregnancy or earlier who are 6 months old or younger; children up to 24 months old with bronchopulmonary dysplasia (BPD), a chronic lung condition of premature birth, that needed treatment in the previous 6 months; and children up to 24 months old with congenital heart disease that significantly affects how the heart pumps blood. It prevents illness; it is not a treatment for a child who already has RSV. Synagis is no longer available in the United States. The manufacturer stopped supplying it at the end of 2025, and US pediatric guidance had already shifted to newer long-acting antibodies: nirsevimab (Beyfortus) and clesrovimab (Enflonsia), which protect a baby through a season with one injection.

How It Works

Palivizumab is a monoclonal antibody: a laboratory-made copy of the kind of protein the immune system produces to recognize a germ. It latches onto the F protein on the surface of RSV, which the virus uses to fuse with and enter the cells lining the airways. Once it is blocked, the virus has a harder time infecting cells and spreading between them. This is borrowed, or passive, protection. Unlike a vaccine, it does not teach the child's immune system to make its own antibodies. The antibody works right away but is gradually cleared from the body, which is why protection lasts only about a month and the injection has to be repeated through the season.

Dosage & Administration

Synagis is given by a healthcare provider as an injection into the thigh muscle once a month during RSV season. The dose is based on the child's weight, so it is recalculated as the baby grows, and a larger dose may be split into two injections. The first dose is ideally given just before the season starts (in much of the US, the season has typically run from fall through spring), and if the season has already begun, as soon as possible. In the original studies children received five monthly doses. Keeping the schedule matters: each dose protects for roughly a month, and spacing doses further apart or using lower doses has not been shown to work. If a dose is missed, the care team will reschedule it as soon as they can. Children with heart disease who have open-heart surgery on a heart-lung bypass machine need an extra dose soon after surgery, because the bypass lowers the antibody level in the blood.

Side Effects

Most children have no noticeable reaction. In the main studies, fever and rash were the most common side effects, though they occurred only slightly more often than in children given a placebo. Severe allergic reactions (anaphylaxis) are rare but can be life threatening, and they can occur after the first dose or a later one. Call 911 or get emergency help right away if a child develops swelling of the lips, tongue, face or throat, trouble breathing, bluish skin or lips, sudden floppiness or unresponsiveness, or widespread hives after an injection. A child who has had a serious allergic reaction to Synagis should not receive it again.

Interactions & Warnings

No important drug interactions are known, and children in the studies received routine childhood vaccines, inhaled breathing medicines and steroids alongside it without extra side effects. Because it is a muscle injection, the provider should know if a child has a bleeding disorder, low platelets or bruises easily. Palivizumab can make some rapid RSV tests (those that detect viral proteins) read falsely negative, while PCR tests (which detect the virus's genetic material) are not affected. If a child getting Synagis seems sick with a respiratory illness, let the clinician know about the injections so test results are read in context.

What to Expect

Synagis lowers the chance of a serious RSV illness but does not remove it. In the main trials, about 5 in 100 high-risk children who received it were hospitalized with RSV during the season, compared with about 10 in 100 who received a placebo. It did not clearly change the number of deaths, and among children who were still hospitalized, the illness was not shown to be milder. In practice it means a monthly clinic visit through the season, and keeping every appointment. If a child catches RSV partway through the season, the monthly doses continue, since a child can be infected again. Because Synagis is no longer sold in the US, families with a child who qualifies for RSV protection will now be offered a newer single-dose antibody instead.

Questions to Ask Your Doctor

  1. 1.Does my child still need RSV protection this season, and which antibody would you recommend now that Synagis is no longer available?
  2. 2.How is a single injection of nirsevimab or clesrovimab different from the monthly Synagis shots my child had before?
  3. 3.If my child has heart surgery during RSV season, will an extra dose be needed afterward?
  4. 4.What breathing or feeding changes during RSV season should prompt a call to you?

Last reviewed • Oct 2026

Educational content, not medical advice.